Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food and Drug Administration (FDA) to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%. Lupin shall commence promoting the product shortly.

Lupin’s Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is an AT rated generic equivalent of Mylan Pharmaceuticals, Inc.’s (formerly held by Delcor Asset Corporation) Triamcinolone Acetonide Cream, 0.025% and 0.1%. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. had US sales of USD 55.7 million (IMS MAT Sep 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 6^th and the 8^th largest generics pharmaceutical company by market capitalization and sales globally (September 30^th, 2016, Bloomberg). The Company is the 5^th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3^rd largest Indian pharmaceutical company by revenues; the 6^th largest generic pharmaceutical player in Japan and the 4^th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31^st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact – 

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

or

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Email: arvindbothra@lupin.com

 *Safe Harbor Statement